AMO ophthalmic viscosurgical device obtains CE Mark of Approval

Article

Abbott Medical Optics' Healon EndoCoat has received the European CE Mark of approval.

Abbott Medical Optics' Healon EndoCoat has received the European CE Mark of approval.

The viscous, low molecular ophthalmic viscosurgical device (OVD) is part of the Healon family and is currently available in Europe, Canada and New Zealand. The Food and Drug Administration (FDA) is presently reviewing the OVD for approval in the US.

Healon EndoCoat can be used as a surgical aid in cataract extraction, corneal transplantation and glaucoma filtration surgery and intraocular lens (IOL) implantation.

The properties of the approved OVD include the 25-gauge cannula delivery system with a guard. The OVD also lubricates and protects the eye during IOL implantation and can be combined with the original Healon OVD, Healon GVD OVD and Healon5 OVD.

Dr Donald Nixon, surgical director of TriMed Eye Center, Ontario, Canada, said: "The OVD plays an essential role in my cataract surgeries for overall endothelial cell preservation and patient safety."

Customers who presently order shipments of the Vitrax II OVD will be automatically updated to the Healon EndoCoat OVD.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.